The earnings call highlighted strong revenue growth, a significant increase in adjusted EBITDA, and successful diversification of the portfolio. However, there were concerns about the flat sales of CYTOGAM and potential indirect impacts of tariffs and global trade changes. The high tax rate also raised questions, but the overall outlook remains positive with reiterated guidance and ongoing expansion efforts.

Company Guidance -

Q2 2025

During Kamada's Q1 2025 earnings call, the company reported strong financial results and reiterated its annual guidance. Total revenues for the first quarter increased by approximately 17% year-over-year to $44 million, driven by higher sales of GLASSIA, KAMRAB in ex-U.S. markets, and VARIZIG, along with GLASSIA royalties income. Adjusted EBITDA rose by 54% to $11.6 million. Kamada anticipates annual revenues of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million for 2025, reflecting growth of 12% and 17% respectively over 2024. The company continues to focus on its four-pillar growth strategy, which includes organic commercial growth, business development, plasma collection expansion, and advancing its Phase 3 inhaled Alpha-1 program. Kamada also launched a comprehensive post-marketing research program for CYTOGAM, aiming to enhance the management of CMV disease, and plans to introduce additional biosimilars to boost its distribution business.

Strong Revenue Growth

Total revenues for Q1 2025 were $44 million, marking an approximately 17% increase year-over-year.

Significant Increase in Adjusted EBITDA

Adjusted EBITDA reached $11.6 million, representing a 54% increase over the previous year.

Diversified Portfolio Performance

Growth was driven by increased sales of GLASSIA and KAMRAB in ex-U.S. markets, as well as VARIZIG sales and GLASSIA royalties income.

Guidance for 2025

The company is reiterating its 2025 annual guidance of $178 million to $182 million in revenues and $38 million to $42 million of adjusted EBITDA.

Successful Launch of Biosimilars

Following the first biosimilar product launch in Israel, two additional biosimilars are expected to launch later this year.

Expansion of Plasma Collection

The opening of a new plasma collection center in San Antonio, Texas, which supports over 50 donor beds, is expected to contribute significantly to annual revenues.

Ongoing Phase 3 Clinical Trial

Progress in the pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy is on track with an interim futility analysis expected by the end of 2025.

Kamada (KMDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KMDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	0.09 / -	0.084	―	―	―
May 14, 2025	2025 (Q1)	0.07 / 0.07	0.044	65.91% (+0.03)	―
Mar 05, 2025	2024 (Q4)	0.05 / 0.07	0.097	-24.74% (-0.02)	―
Nov 13, 2024	2024 (Q3)	0.07 / 0.07	0.066	12.12% (<+0.01)	―
Aug 14, 2024	2024 (Q2)	0.06 / 0.08	0.045	86.67% (+0.04)
May 08, 2024	2024 (Q1)	0.06 / 0.04	0	―	―
Mar 06, 2024	2023 (Q4)	0.05 / 0.10	0.075	29.33% (+0.02)	―
Nov 13, 2023	2023 (Q3)	0.03 / 0.07	0.018	266.67% (+0.05)	―
Aug 16, 2023	2023 (Q2)	0.02 / 0.04	-0.08	156.25% (+0.13)	―
May 24, 2023	2023 (Q1)	0.03 / 0.00	-0.037	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KMDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$6.89	$7.05	+2.32%
Mar 05, 2025	$6.42	$6.90	+7.48%
Nov 13, 2024	$6.10	$5.86	-3.93%
Aug 14, 2024	$5.40	$5.18	-4.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kamada (KMDA) report earnings?

Kamada (KMDA) is schdueled to report earning on Aug 13, 2025, Before Open (Confirmed).

What is Kamada (KMDA) earnings time?

Kamada (KMDA) earnings time is at Aug 13, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KMDA EPS forecast?

KMDA EPS forecast for the fiscal quarter 2025 (Q2) is 0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing